Polaryx Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Polaryx Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $9.83M.
- Polaryx Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $0.00.
- Polaryx Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $4.59M.
- Polaryx Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $8.84M, a 13.50% increase from fiscal 2024.
- Polaryx Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $7.79M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $9.83M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $8.84M 10-K · filed 2026-03-24 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | |
| 2025-03-31 | $4.59M 10-Q · filed 2026-05-15 | |
| 2024-12-31 | $7.79M 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |